Professional Documents
Culture Documents
M
/
g
p
r
o
t
e
i
n
Fig. 4. (a) Percent contraction of endothelium intact aortic rings to different
concentration of l-NAME. The aortic rings obtained from N ( g), D ( ?),
N-MET ( >) and D-MET ( g) groups were moderately contracted with
phenylephrine before obtaining cumulative responses to l-NAME. (b) Aortic
nitrite levels determined from N, D, N-MET and D-MET groups. Values are
expressed as meanTS.E.M. *p <0.05, compared to D;
#
p <0.05, compared to N
(N=Normal, D=Diabetic).
Table 2
Superoxide dismutase, catalase, reduced glutathione and lipid peroxidation
levels in liver, kidney and aorta of nondiabetic control (N), diabetic control (D),
nondiabetic animals treated with metformin (N-MET) and diabetic animals
treated with metformin (D-MET)
Groups Liver Kidney Aorta
Superoxide dismutase
(Unit/mg protein)
N 8.23T0.241 8.83T0.056 6.19T0.118
D 4.67T0.383
a
5.37T0.135
a
4.29T0.148
a
N-MET 7.97T0.176 8.74T0.087 5.82T0.167
D-MET 7.21T0.214
b
7.65T0.133
b
5.89T0.154
b
Catalase (AM of H
2
O
2
consumed /(min mg protein)
N 11.36T0.47 11.43T0.49 5.88T0.064
D 7.73T0.415
a
7.25T0.63
a
3.64T0.136
a
N-MET 11.80T0.412 11.74T0.25 5.69T0.042
D-MET 9.83T0.812
b
9.76T0.34
b
5.56T 0.195
b
Reduced glutathione
(Ag of GSH/mg protein)
N 9.86T0.107 11.53T0.054 2.83T0.078
D 4.65T0.047
a
4.34T0.132
a
0.83T0.024
a
N-MET 9.56T0.112 11.18T0.125 2.42T0.073
D-MET 7.84T0.214
b
8.53T0.367
b
1.65T0.086
b
Lipid peroxidation
(nM of MDA/mg protein)
N 0.786T0.036 0.853T0.034 0.221T0.011
D 1.458T0.116
a
1.783T0.122
a
0.585T0.062
a
N-MET 0.790T0.069 0.971T0.056 0.219T0.086
D-MET 0.978T0.138
b
0.912T0.157
b
0.307T0.059
b
Values are expressed as meanTS.E.M. (n =67).
a
p <0.001, compared to nondiabetic control group.
b
p <0.01, compared to diabetic control.
J.B. Majithiya, R. Balaraman / Life Sciences 78 (2006) 26152624 2619
and Ach-induced relaxation was completely blocked due
to presence of l-NAME or methylene blue (Fig. 3a,b).
On the other hand, the presence of indomethacin
decreased Ach-induced relaxation in both nondiabetic
groups. The decreased Ach-induced relaxation in diabetic
control group was significantly increased by metformin
treatment. Ach-induced relaxation in diabetic groups (control
and metformin-treated) were unaltered due to presence of
indomethacin while Ach-induced relaxation was completely
blocked due to presence of l-NAME or methylene blue
(Fig. 3c,d).
Basal nitric oxide release and aortic nitrite levels
Addition of l-NAME in aortic preparation resulted in
increasing contraction of the aorta of all the groups.
Contraction was significantly higher in metformin-treated
diabetic group as compared to diabetic control group
(Fig. 4a). Aortic nitrite levels of various groups are shown
in Fig. 4b. Aortic nitrite levels were significantly ( p <0.05)
higher in diabetic control group as compared to nondia-
beticcontrol group. Metformin treatment significantly
( p <0.05) reduced aortic nitrite of diabetic animals as
compared to diabetic control group. There was no significant
change on aortic nitrite levels due to metformin treatment in
nondiabetic animals as compared to nondiabetic control
group.
Superoxide dismutase, catalase, reduced glutathione and lipid
peroxidation
Oxidative stress was significantly ( p <0.001) increased
in liver, kidney and aorta of diabetic control group
as compared to nondiabetic control group (Table 2).
SOD, CAT and GSH were significantly decreased while
lipid peroxidation was significantly increased in diabetic
control group. Metformin treatment significantly ( p <0.01)
increased levels of endogenous antioxidants (SOD, CAT
and GSH) in liver, kidney and aorta as compared to dia-
betic control (Table 2). Moreover, lipid peroxidation was
also significantly ( p <0.01) decreased in liver, kidney and
aorta of diabetic animals treated with metformin as
0.0
0.5
1.0
1.5
2.0
a
vehicle
1 mM
10 mM
*
*
-9 -8 -7 -6 -5
0.0
0.5
1.0
1.5
2.0
*
*
b
log [PE](M)
T
e
n
s
i
o
n
(
g
)
0.1 M
1 M
10 M
100 M
T
e
n
s
i
o
n
(
g
)
Fig. 5. Concentration response curve of phenylephrine on aortic rings obtained
from untreated age matched non diabetic rats (a) and STZ diabetic rats (b) in
presence of varying concentration of metformin (0.1 AM10 mM). Values are
expressed as meanTS.E.M. *p <0.05, compared to vehicle.
0
20
40
60
80
100
120
a
vehicle
1 mM
10 mM
0.1 M
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100
120
b
*
*
*
log [Ach] (M)
%
R
e
l
a
x
a
t
i
o
n
%
R
e
l
a
x
a
t
i
o
n
1 M
10 M
100 M
Fig. 6. Concentration dependent relaxation of acetylcholine on aortic rings
(with intact endothelium) of untreated age matched non diabetic rats (a) and
STZ diabetic rats (b), precontracted with PE and in presence of varying
concentration of metformin (0.1 AM10 mM). Tension is expressed as
percentage relaxation of initial response to PE. Values are expressed as
meanTS.E.M. *p <0.05, compared to vehicle.
J.B. Majithiya, R. Balaraman / Life Sciences 78 (2006) 26152624 2620
compared to diabetic control. There was no significant
change in SOD, CAT, GSH and lipid peroxidation of
nondiabetic groups.
Effect of presence of metformin on concentrationresponse
curve of PE, Ach and SNP in aorta obtained from untreated
nondiabetic and STZ-diabetic rats
The presence of metformin (0.1 AM100 AM) had no
significant effect on contractile effect of PE on aorta of
untreated nondiabetic and diabetic rats (Fig. 5). On the other
hand, the presence of higher concentration of metformin (1
mM and 10 mM) significantly ( p <0.05) decreased the
contractile effect of PE. Metformin caused a concentration-
dependent rightward shift on the contractile response of PE.
Ach completely relaxed aorta obtained from nondiabetic rats
but relaxation was impaired in aortic rings from diabetic rats.
There was no significant change in relaxation response to Ach
in aorta of nondiabetic rats due to the presence of metformin
(Fig. 6). Presence of lower concentration of metformin (0.1
AM10 AM) had no significant effect on relaxation response to
Ach in aorta of diabetic rats, but the presence of higher
concentration of metformin (100 AM and higher) significantly
( p <0.05) increased relaxation (Fig. 6). SNP-induced relaxa-
tion in case of nondiabetic rats (data not shown) and diabetic
rats (Fig. 7) were similar and there was no significant effect of
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
120
Vehicle
0.1 M
10 mM
log [SNP] (M)
%
R
e
l
a
x
a
t
i
o
n
1 M
10 M
100 M
1 M
Fig. 7. Concentration dependent relaxation of sodium nitroprusside on
endothelium denuded aortic rings of untreated age matched STZ diabetic rats
precontracted with PE and in presence of varying concentration of metformin
(0.1 AM10 mM). Tension is expressed as percentage relaxation of initial
response to PE. Values are expressed as meanTS.E.M.
0
25
50
75
100
125
a
%
R
e
l
a
x
a
t
i
o
n
-9 -8 -7 -6 -5 -4 -3 -2 -1 0
0
20
40
60
80
100
120
PE + E
PE + E + L NAME
PE - E
b
log [Metformin] (M)
%
R
e
l
a
x
a
t
i
o
n
Fig. 8. Concentration-dependent relaxation of metformin on untreated age
matched non diabetic rats (a) and STZ diabetic rats (b), precontracted with PE
with intact endothelium (+E), PE with denuded endothelium (E), PE with
intact endothelium (+E) in presence of 100 M l-NAME. Values are expressed
as meanTS.E.M.
0
25
50
75
100
125
a
%
R
e
l
a
x
a
t
i
o
n
-9 -8 -7 -6 -5 -4 -3 -2 -1 0
0
20
40
60
80
100
120
b
PE + Glybenclamide
PE + TEA + 4AP
PE + TEA
PE + 4AP
PE + Ba
+
PE + vehicle
log [Metformin] (M)
%
R
e
l
a
x
a
t
i
o
n
Fig. 9. Concentration dependent relaxation of metformin on untreated age
matched non diabetic rats (a) and STZ diabetic rats (b), precontracted with PE
( n) with intact endothelium, in presence of 1 mM of TEA ( >), 100 AM
of Ba
+
( g), 1 mM of 4-AP ( ?), 10 AM of Glybenclamide ( q) and (1
mM) TEA+ (1 mM) 4-AP ( r). Values are expressed as meanTS.E.M.
J.B. Majithiya, R. Balaraman / Life Sciences 78 (2006) 26152624 2621
SNP-induced relaxation due the presence of metformin (0.1
AM10 mM) as compared to vehicle.
Relaxation response to metformin on precontracted aorta
obtained from untreated nondiabetic and STZ-diabetic rats
Addition of metformin (10 nM10 mM) to PE contracted
rings produced concentration-dependent relaxation in nondia-
betic and diabetic rats (Fig. 8). Presence of l-NAME
completely blocked metformin-induced relaxation at lower
concentration (10 nM30 M), but not at concentrations at
above 30 M. Removal of endothelium blocked metformin-
induced relaxation at concentration lower than 30 M but not
above 30 M. Further based on our observations that depolar-
ization with KCl attenuated the potency of metformin, we
attempted to determine the contribution of K
+
channels to
metformin-mediated relaxation. There was no significant effect
on metformin-mediated relaxation due to the presence of
barium ion or glybenclamide (Fig. 9). While metformin-
mediated relaxation was partially blocked due to the presence
of 4-aminopyridine and TEA, combination of 4-aminopyridine
and TEA further blocked metformin-induced relaxation.
Discussion
The blood pressure of 8-week STZ-diabetic rats was
significantly higher as compared to nondiabetic control. The
results are in concurrence with our previous study where the
blood pressure was increased after 8 weeks of STZ adminis-
tration and Ach-induced relaxation was impaired in aortic rings
(Majithiya et al., 2005). Administration of metformin for 4
weeks restored the elevated blood pressure, reduced the
enhanced contractibility to PE- and Ach-induced relaxation
was restored. In metformin-treated STZ-diabetic rats, there was
an increase in Ach-induced relaxation which may be due to
involvement of NO pathway since the relaxation was blocked
in the presence of l-NAME and not in the presence of
indomethacin. Moreover, relaxation to Ach was also blocked in
the presence of cGMP blocker, methylene blue, suggesting a
role of cGMP in elevated relaxation to Ach in STZ-diabetic
aorta. Further, tone-related basal nitric oxide studies showed
that metformin treatment significantly increased the basal nitric
oxide release in aortas of STZ-diabetic rats. This is in
accordance with the study of Sartoretto et al. (2005), where it
was shown that metformin treatment increases nitric oxide
activity but not expression and improves microvascular
reactivity in n- STZ-diabetic rats.
Metformin is reported to lower blood pressure in various
animal modelsfructose-fed rats (Verma et al., 1994), OLETF
rats (Kosegawa et al., 1996), SHR (Bhalla et al., 1996; Muntzel
et al., 1999) and insulin-resistant rats (Katakam et al., 2000). In
this study, metformin had no significant effect on blood
glucose levels in nondiabetic and diabetic rats. In the present
study, lower dose of metformin (150 mg/kg) was used and it
did not produce any significant effect on blood glucose level
Metformin reduces blood glucose level at a much higher dose
of 450500 mg/kg in STZ-diabetic rats (Stepensky et al.,
2002). Hence, the results produced are independent of
metformin effect on blood glucose level. Recently metformin
is reported to improve microvascular function in type 2 diabetic
model without improving hyperglycemia (Sartoretto et al.,
2005). Metformin is reported to reduce blood pressure by a-
adrenergic blockade or ganglionic blockade (Muntzel et al.,
1997), by inhibiting sympathetic tone (Petersen and Dibona,
1996), by direct effect on vascular smooth muscle (Sharma and
Bhalla, 1995; Peuler et al., 1997; Verma et al., 1996) or by
opening of voltage-dependent potassium channels (K
v
)
(Mather et al., 2001).
In the present study, in vitro experiments were carried out to
investigate the direct effect of metformin on aorta of untreated
nondiabetic and STZ-diabetic rats. PE-induced contraction and
Ach-induced relaxation studies in the presence of various
concentration of metformin showed that low concentration of
this drug did not have any effect on the PE-induced contraction
or Ach-induced relaxation. But presence of higher concentra-
tion (greater than 1 mM) of metformin caused significant
changes in doseresponse curves of PE and Ach. Further
metformin-induced relaxation in rings with intact endothelium
was blocked in the presence of l-NAME at lower concentra-
tions but not at higher concentrations. The effect of metformin-
induced relaxation in the presence of various potassium
channel inhibitors shows that the vasorelaxation induced by
metformin can be attributed in part to the opening of K
v
and
K
Ca+
channels. Further there was no relaxation at lower
concentration, relaxation increased only above 10 M. Similarly
significant change in PE-induced contraction and Ach-induced
relaxation was present at higher concentration (greater than 1
mM). Pharmacokinetic studies by Stepensky et al. (2002) have
shown that concentration close to 120 M was found in blood
after administering 500 mg/kg of metformin orally. In the
present study much lower dose of metformin was administered,
hence blood pressure lowering effect cannot be completely
attributed to direct effect of metformin on vascular smooth
muscle. Treatment with metformin caused reduction in
oxidative stress; it may be one of the reasons of decrease in
blood pressure coupled with restored endothelium function of
STZ-diabetic rats.
Nitric oxide is rapidly inactivated by O
2
radical may be
involved in the accelerated break down of nitric oxide
(Gryglewski et al., 1986; Rubanyi and Vanhoutte, 1986).
Moreover it has been shown that rapid destruction of nitric
oxide occurs in streptozotocin-induced diabetic rats (Kamata
and Kobayashi, 1996). The protective effect of metformin
against oxidative stress may prevent the breakdown of nitric
oxide, which may improve vascular function. Similar observa-
tions have reported that metformin reduce oxidative stress in
various animal models (Bonnefont-Rousselot et al., 2003;
Srinivasan and Carani, 2002; Faure et al., 1999). Metformin is
also reported to modulate nitric oxide synthase (Kumar et al.,
2001) and restore endothelial function (Mather et al., 2001).
Moreover recently metformin is reported to increase nitric
oxide activity without increasing nitric oxide expression in type
2 diabetic n-STZ model (Sartoretto et al., 2005). This increase
J.B. Majithiya, R. Balaraman / Life Sciences 78 (2006) 26152624 2622
in nitric oxide activity may be due to the reduction in oxidative
stress by metformin. Zou et al. (2004) have shown that
metformins action is mediated by the activation of AMP-
activated protein kinase via mitochondrial reactive nitrogen
species. On the contrary, Gallo et al. (2005) have recently
shown that metformin stimulates AMPK on one site, whereas it
inhibits PKC on the other. Gallo et al. (2005) has also shown
that metformin action involves its antioxidant effect. Our study
is in accordance with Gallo et al. (2005), showing the
antioxidant effect of metformin. Hence, the restored endothelial
function could also be attributed to the protective effect of
metformin against oxidative stress.
Hence, the restored endothelial function along with direct
effect of metformin on aortic rings and protective effect of
metformin against oxidative stress altogether may attribute to
metformins beneficial effect in STZ-diabetic rats.
Acknowledgement
Financial assistance provided by The M.S. University of
Baroda to Mr. Jayesh B Majithiya is highly acknowledged.
References
Aebi, H., 1984. Oxidoreductases acting on groups other than CHOH: catalase.
In: Colowick, S.P., Kaplan, N.O., Packer, L. (Eds.), Methods in Enzymol-
ogy. Academic Press, London, pp. 121125.
Bafna, P.A., Balaraman, R., 2004. Anti-ulcer and antioxidant activity of DHC-
1, a herbal formulation. Journal of Ethnopharmacology 90, 123127.
Bhalla, R.C., Toth, K.F., Tan, E., Bhatty, R.A., Mathias, E., Sharma, R.V., 1996.
Vascular effects of metformin: possible mechanisms for its antihypertensive
action in the spontaneously hypertensive rat. American Journal of
Hypertension 9, 570576.
Bonnefont-Rousselot, D., Raji, B., Walrand, S., GardeS-Albert, M., Jore, D.,
Legrand, A., Peynet, J., Vasson, M.P., 2003. An intracellular modulation of
free radical production could contribute to the beneficial effects of
metformin towards oxidative stress. Metabolism 52, 586589.
Calle-Pascual, A.L., Garcia-Honduvilla, J., Martin-Alvarez, P.J., Vara Calle,
J.R., Munguira, M.E., Maranes, J.P., 1995. Comparison between
acarbose, metformin, and insulin treatment in type 2 diabetic patients
with secondary failure to sulfonylurea treatment. Diabetes & Metabolism
21, 256260.
Campbell, I.W., Duncan, C., Patton, N.W., Broadhead, T., Tucker, G.T., Woods,
H.F., 1987. The effect of metformin on glycaemic control, intermediary
metabolism and blood pressure in non-insulin-dependent diabetes mellitus.
Diabetes & Metabolism 4, 337341.
Faure, P., Rossini, E., Wiernspeger, N., Richard, M.J., Favier, A., Halimi, S.,
1999. An insulin sensitizer improves the free radical defense system
potential and insulin sensitivity in high fructose-fed rats. Diabetes 48,
353357.
Gallo, A., Ceolotto, G., Pinton, P., Iori, E., Murphy, E., Rutter, G.A., Rizzuto,
R., Semplicini, A., Avogaro, A., 2005. Metformin prevents glucose-induced
protein kinase c-h2 activation in human umbilical vein endothelial cells
through an antioxidant mechanism. Diabetes 54, 11231131.
Giugliano, D., Acampora, R., De Rosa, N., Buoninconti, R., Di Maro, G.,
Donofrio, F., Marfella, R., 1993. Metformin improves glucose lipid
metabolism, and reduces blood pressure in hypertensive, obese women.
Diabetes Care 16, 13871390.
Gryglewski, R.J., Palmer, R.M.J., Moncada, S., 1986. Superoxide anion is
involved in the breakdown of endothelium-derived vascular relaxing factor.
Nature 320, 454456.
GudbjoRnsdottir, S., Friberg, P., Elam, M., Attvall, S., LoNnroth, P., Wallin,
G., 1994. The effect of metformin and insulin on sympathetic nerve activity,
norepinephrine spillover and blood pressure in obese, insulin resistant,
normoglycemic, hypertensive men. Blood Pressure 3, 394403.
Guevara, I., Iwanejko, J., Dembinska-Kiec, A., Pankiewicz, J., Wanat, A.,
Anna, P., Golabek, I., Bartus, S., Malczewska-Malec, M., Szczudlik, A.,
1998. Determination of nitrite/nitrate in human biological material by the
simple Griess reaction. Clinica Chimica Acta 274, 177188.
Hayashi, T., Fukuto, J.M., Ignarro, L.J., Chaudhuri, G., 1992. Basal release of
nitric oxide from aortic rings is greater in female rabbits than in male
rabbits: implications for atherosclerosis. Proceedings of the National
Academy of Sciences of the United States of America 89, 1125911263.
Kamata, K., Kobayashi, T., 1996. Changes in superoxide dismutase mRNA
expression by streptozotocin-induced diabetes. British Journal of Pharma-
cology 119, 583589.
Kamata, K., Miyata, N., Kasuya, Y., 1989. Impairment of endothelium-
dependent relaxation and changes on levels of cyclic GMP in aorta from
streptozotocin-induced diabetic rats. British Journal of Pharmacology 97,
614618.
Katakam, P.V.G., Ujhelyi, M.R., Hoenig, M., Miller, A.W., 2000. Metformin
improves vascular function in insulin-resistant rats. Hypertension 35,
108112.
Kobayashi, T., Kamata, K., 1999. Relationship among cholesterol, superoxide
anion and endothelium-dependent relaxation in diabetic rats. European
Journal of Pharmacology 367, 213222.
Kosegawa, I., Katayama, S., Kikuchi, C., Kashiwabara, H., Negishi, K., Ishii,
J., Inukai, K., Oka, Y., 1996. Metformin decreases blood pressure and
obesity in OLETF rats via improvement of insulin resistance. Hypertension
Research 19, 3741.
Kumar, V.B., Bernardo, A.E., Vyas, K., Franko, M., Farr, S., Lakshmanan, L.,
Buddhiraju, C., Morley, J.E., 2001. Effect of metformin on nitric oxide
synthase in genetically obese (ob/ob) mice. Life Sciences 69, 27892799.
Landin, K., Tengborn, I., Smith, U., 1991. Treating insulin resistance in
hypertension with metformin reduces both blood pressure and metabolic
risk factors. Journal of Internal Medicine 229, 181187.
Majithiya, J.B., Parmar, A.N., Balaraman, R., 2005. Pioglitazone, a PPAR g
agonist, restores endothelial function in aorta of streptozotocin-induced
diabetic rats. Cardiovascular Research 66, 150161.
Mather, K.J., Verma, S., Anderson, T.J., 2001. Improved endothelial function
with metformin in type 2 diabetes mellitus. Journal of the American College
of Cardiology 37, 13441350.
Matthaei, S., Stumvoll, M., Kellerer, M., Haring, H., 2000. Pathophysiology
and pharmacological treatment of insulin resistance. Endocrine Reviews 21,
585618.
Mishra, H.P., Fridovich, I., 1972. The role of superoxide anion in the auto-
oxidation of epinephrine and a simple assay for superoxide dismutase.
Journal of Biological Chemistry 247, 31703175.
Moller, D.E., 2001. New drug targets for type 2 diabetes and the metabolic
syndrome. Nature 414, 821827.
Moron, M.S., Depierre, J.W., Mannervik, B., 1979. Levels of glutathione,
glutathione reductase and glutathione S-transferase activities in rat lung and
liver. Biochimca and Biophysica Acta 582, 6778.
Muntzel, M.S., Abe, A., Petersen, J.S., 1997. Effects of adrenergic, cholinergic,
and ganglionic blockade on acute depressor responses to metformin in
spontaneously hypertensive rats. Journal of Pharmacology and Experimen-
tal Therapeutics 281, 618623.
Muntzel, M.S., Hamidou, I., Barrett, S., 1999. Metformin attenuates salt-
induced hypertension in spontaneously hypertensive rats. Hypertension 33,
11351140.
Oyama, Y., Kawasaki, H., Hattori, Y., Kanno, M., 1986. Attenuation of
endothelium-dependent relaxation in aorta from diabetic rats. European
Journal of Pharmacology 131, 7578.
Petersen, J.S., Dibona, G.F., 1996. Acute sympathoinhibitory actions of
metformin in spontaneously hypertensive rats. Hypertension 27, 619625.
Peuler, J.D., Miller, J.A., Bourghli, M., Zammam, H.Y., Soltis, E.E., Sowers,
J.R., 1997. Disparate effects of antidiabetic drugs on arterial contraction.
Metabolism 46, 11991205.
Rubanyi, G.M., Vanhoutte, P.M., 1986. Superoxide anions and hyperoxia
inactivate endothelium-derived relaxing factor. American Journal of
Physiology 250, H822H827.
J.B. Majithiya, R. Balaraman / Life Sciences 78 (2006) 26152624 2623
Sartoretto, J.L., Melo, G.A., Carvalho, M.H., Nigro, D., Passaglia, R.T.,
Scavone, C., Cuman, R.K., Fortes, Z.B., 2005. Metformin treatment
restores the altered microvascular reactivity in neonatal streptozotocin-
induced diabetic rats increasing NOS activity, but not NOS expression. Life
Science 77 (12), 26762689.
Senses, V., Ozyazgan, S., Ince, E., Tuncdemir, M., Kaya, F., Ozturk, M.,
Sultuybek, G., Akkan, A.G., 2001. Effect of 5-aminoimidazole-4-carbox-
amide riboside (AICA-r) on isolated thoracic aorta responses in streptozo-
tocin-diabetic rats. Journal of Basic and Clinical Physiology and
Pharmacology 12, 227248.
Sharma, R.V., Bhalla, R.C., 1995. Metformin attenuates agonist-stimulated
calcium transients in vascular smooth muscle cells. Clinical and Experi-
mental Hypertension 17, 913929.
Slater, T.F., Sawyer, B.C., 1971. The stimulatory effects of carbon tetrachloride
and other halogenoalkanes or peroxidative reactions in rat liver fractions in
vitro. Biochemical Journal 123, 805814.
Srinivasan, S., Carani, V.A., 2002. Metformin improves liver antioxidant
potential in rats fed a high-fructose diet. Asia Pacific Journal of Clinical
Nutrition 11, 319322.
Stepensky, D., Friedman, M., Raz, I., Hoffman, A., 2002. Pharmacokinetic
pharmacodynamic analysis of the glucose-lowering effect of metformin in
diabetic rats reveals first-pass pharmacodynamic effect. Drug Metabolism
and Disposition 30, 861868.
Verma, S., Bhanot, S., Mcneill, J.H., 1994. Antihypertensive effects of
metformin in fructose-fed hyperinsulinemic, hypertensive rats. Journal of
Pharmacology and Experimental Therapeutics 271, 13341337.
Verma, S., Bhanot, S., Mcneill, J.H., 1996. Decreased vascular reactivity in
metformin-treated fructose-hypertensive rats. Metabolism 45, 10531055.
Zanetti, M., Sato, J., Katusic, Z.S., Obrien, T., 2001. Gene transfer of
superoxide dismutase isoforms reverses endothelial dysfunction in diabetic
rabbit aorta. American Journal of Physiology 280, H2516H2523.
Zou, M.H., Kirkpatrick, S.S., Davis, B.J., Nelson, J.S., Wiles, W.G., Schlattner,
U., Neumann, D., Brownlee, M., Freeman, M.B., Goldman, M.H., 2004.
Activation of the AMP-activated protein kinase by the anti-diabetic drug
metformin in vivo: role of mitochondrial reactive nitrogen species. Journal
of Biological Chemistry 279, 4394043951.
J.B. Majithiya, R. Balaraman / Life Sciences 78 (2006) 26152624 2624